Vaxart Inc (VXRT)

Apr 28, 2025

Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News

Apr 28, 2025

Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025

Apr 28, 2025

Federal government lifts hold on Peninsula biotech company's vaccine trial - The Business Journals

Apr 28, 2025

Apr 28, 2025

Vaxart resumes BARDA-funded trial activities - Investing.com

Apr 28, 2025

Apr 22, 2025

Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News

Apr 22, 2025

Apr 19, 2025

Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com

Apr 19, 2025

Apr 16, 2025

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire

Apr 16, 2025

Apr 16, 2025

Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan

Apr 16, 2025

Apr 16, 2025

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - The Globe and Mail

Apr 16, 2025

Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025

Apr 11, 2025

Proprietary - Vaxart Inc.

Apr 11, 2025

Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Mar 30, 2025

RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville

Mar 30, 2025

Mar 28, 2025

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 28, 2025

Mar 27, 2025

Vaxart reports inducement grants under Nasdaq listing rule - TipRanks

Mar 27, 2025

Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com

Mar 27, 2025

Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Mar 27, 2025

Mar 27, 2025

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 27, 2025

Mar 27, 2025

Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan

Mar 27, 2025

Mar 27, 2025

B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener

Mar 27, 2025

Mar 24, 2025

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 24, 2025

Mar 22, 2025

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 22, 2025

Mar 21, 2025

Oral - Vaxart Inc.

Mar 21, 2025

Mar 21, 2025

Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE

Mar 21, 2025

Mar 21, 2025

Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE

Mar 21, 2025

Mar 21, 2025

Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener

Mar 21, 2025

Mar 21, 2025

RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals

Mar 21, 2025

Mar 21, 2025

Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus

Mar 21, 2025

Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance

Mar 21, 2025

Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com

Mar 21, 2025

Mar 21, 2025

Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks

Mar 21, 2025

Mar 21, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire

Mar 21, 2025

Mar 20, 2025

Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India

Mar 20, 2025

Mar 20, 2025

Vaxart Inc. (VXRT) reports earnings - Quartz

Mar 20, 2025

Mar 20, 2025

Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener

Mar 20, 2025

Mar 20, 2025

Vaxart, Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 20, 2025

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan

Mar 20, 2025

Mar 19, 2025

FDA Mid-Month ID Food Recall Safety Updates - ContagionLive

Mar 19, 2025

Mar 14, 2025

Pipeline - Vaxart Inc.

Mar 14, 2025

Mar 13, 2025

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire

Mar 13, 2025

Mar 13, 2025

Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq

Mar 13, 2025